Aurinia Pharmaceuticals Inc. (AUPH) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Aurinia Pharmaceuticals Inc.'s filing signal turned positive.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, notably launching LUPKYNIS(R) (voclosporin) in January 2021 as the first FDA-approved oral treatment for active lupus nephritis (LN). The company markets LUPKYNIS directly in the U.S. and through its collaboration partner, Otsuka Pharmaceutical Co., Ltd., in Japan and Europe. Aurinia is also advancing aritinercept, a dual inhibitor of BAFF and APRIL, for potential treatment of other autoimmune conditions. In 2025, LUPKYNIS generated $271.3 million in net product sales, a 25% increase from the prior year, reflecting growing market penetration. The company operates with a lean structure, employing 128 full-time equivalents as of February 2026.

Primary revenue is driven by net product sales of LUPKYNIS in the United States, supplemented by license, collaboration, and royalty revenue from its partnership with Otsuka for ex-U.S. markets.